Royalty Pharma (RPRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.32
- EPS estimate
- $1.27
- EPS surprise
- +3.82%
- Revenue surprise
- +1.85%
- Revenue
- $773.0M
- Revenue estimate
- $758.9M
- Reported
- Aug 5, 2026
Royalty Pharma reported Q2 2026 results on August 5, 2026. Earnings per share were $1.32, beating the $1.27 estimate by 3.82%. Revenue was $773.0 million against a $758.9 million consensus, a 1.85% beat. Compared with Q2 2025, EPS rose about 16% from $1.14 and revenue rose about 6% from $727.0 million.
Results in the table move around from quarter to quarter but trend higher. Annual EPS was $3.70 in 2022, $4.38 in 2023 and $4.01 in 2024, then rose 13% to $4.53 in 2025. The first half of 2026 added up to $2.62 per share, about 39% more than the $1.89 a year earlier. Q1 2023 set the EPS high in the table at $1.60, and revenue peaked at about $1.1 billion in Q4 2022 and Q1 2023. Royalty Pharma beat EPS estimates in 15 of the last 20 quarters, including the last five in a row.
The company reported Q3 between November 5 and November 10 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue stays above year-earlier levels, as it has in each of the last nine quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $1.27 | $1.32 | +3.82% | $773.0M | SEC |
| Q1 2026 | May 6, 2026 | $1.11 | $1.30 | +17.30% | $925.0M | SEC |
| Q4 2025 | Feb 11, 2026 | $1.29 | $1.47 | +14.02% | $874.0M | SEC |
| Q3 2025 | Nov 5, 2025 | $0.99 | $1.17 | +18.08% | $814.0M | SEC |
| Q2 2025 | Aug 6, 2025 | $1.03 | $1.14 | +10.53% | $727.0M | SEC |
| Q1 2025 | May 8, 2025 | $0.95 | $0.75 | −21.40% | $839.0M | SEC |
| Q4 2024 | Feb 11, 2025 | $1.05 | $1.15 | +9.15% | $742.0M | SEC |
| Q3 2024 | Nov 6, 2024 | $0.93 | $0.92 | −1.09% | $735.0M | SEC |
| Q2 2024 | Aug 8, 2024 | $0.97 | $0.96 | −0.39% | $608.0M | SEC |
| Q1 2024 | May 9, 2024 | $0.99 | $0.98 | −0.92% | $717.0M | SEC |
| Q4 2023 | Feb 15, 2024 | $1.01 | $1.15 | +13.74% | $698.4M | SEC |
| Q3 2023 | Nov 8, 2023 | $0.77 | $0.79 | +2.50% | $637.0M | SEC |
| Q2 2023 | Aug 8, 2023 | $0.83 | $0.84 | +1.80% | $544.8M | SEC |
| Q1 2023 | May 9, 2023 | $1.27 | $1.60 | +25.85% | $1.1B | SEC |
| Q4 2022 | Feb 15, 2023 | $1.47 | $1.56 | +5.85% | $1.1B | SEC |
| Q3 2022 | Nov 8, 2022 | $0.71 | $0.73 | +2.45% | $597.0M | SEC |
| Q2 2022 | Aug 4, 2022 | $0.78 | $0.81 | +3.76% | $524.0M | SEC |
| Q1 2022 | May 5, 2022 | $0.73 | $0.60 | −18.00% | $604.9M | SEC |
| Q4 2021 | Feb 15, 2022 | $0.78 | $0.80 | +3.17% | $543.0M | SEC |
| Q3 2021 | Nov 10, 2021 | $0.70 | $0.73 | +3.71% | $586.9M | SEC |
Quarterly revenue
Frequently asked questions
When did Royalty Pharma (RPRX) last report earnings?
Royalty Pharma last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did RPRX beat earnings estimates?
Yes. Royalty Pharma reported EPS of $1.32 for Q2 2026 against a $1.27 estimate — a 3.82% beat.
How much revenue did RPRX report last quarter?
Royalty Pharma reported $773.0M in revenue for Q2 2026, against a consensus estimate of $758.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.